Eli Lilly, Nordisk win dismissal of US antitrust claims over GLP-1 drugs
MLex Summary: Strive Specialties failed to allege a plausible market in its US antitrust case against Eli Lilly and Novo Nordisk over GLP-1 drugs, according to a Texas federal judge. US...To view the full article, register now.
Already a subscriber? Click here to view full article